These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38341131)

  • 1. Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study.
    Su YC; Hsieh PC; Lai EC; Lin YC
    Diabetes Metab; 2024 Mar; 50(2):101522. PubMed ID: 38341131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study.
    Su YC; Hsieh PC; Lai EC; Lin YC; Lin YC
    Diabetes Metab; 2024 Jul; 50(4):101545. PubMed ID: 38777141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
    Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
    Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
    JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
    Riester MR; Zullo AR; Joshi R; Daiello LA; Hayes KN; Ko D; Kim DH; Munshi M; Berry SD
    Diabetes Obes Metab; 2024 Aug; 26(8):3403-3417. PubMed ID: 38779879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study.
    Hsiao FC; Lin CP; Tung YC; Wu CT; Chu PH
    Diabetes Res Clin Pract; 2021 Oct; 180():109076. PubMed ID: 34599973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
    Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
    Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
    [No Abstract]   [Full Text] [Related]  

  • 15. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Cotter G; Davison BA; Edwards C; Senger S; Teerlink JR; Zannad F; Nielsen OW; Metra M; Mebazaa A; Chioncel O; Greenberg BH; Maggioni AP; Ertl G; Sato N; Cohen-Solal A
    Am Heart J; 2021 Oct; 240():73-80. PubMed ID: 34107289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
    Suzuki Y; Kaneko H; Nagasawa H; Okada A; Fujiu K; Jo T; Takeda N; Morita H; Nishiyama A; Gohda T; Suzuki Y; Node K; Yasunaga H; Nangaku M; Komuro I
    Diabetes Obes Metab; 2024 Jun; 26(6):2422-2430. PubMed ID: 38528820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.
    Hsiao FC; Yen KC; Chao TF; Chen SW; Chan YH; Chu PH
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2493-2499. PubMed ID: 35776065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.
    Ahmad A; Sabbour H
    Cardiovasc Diabetol; 2024 Mar; 23(1):99. PubMed ID: 38500154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes mellitus increases the risk of rotator cuff tear repair surgery: A population-based cohort study.
    Huang SW; Wang WT; Chou LC; Liou TH; Chen YW; Lin HW
    J Diabetes Complications; 2016; 30(8):1473-1477. PubMed ID: 27600100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.